Seizure-Induced Up-Regulation of P-Glycoprotein at the Blood-Brain Barrier through Glutamate and Cyclooxygenase-2 Signaling
Increased expression of drug efflux transporters at the blood-brain barrier accompanies epileptic seizures and complicates therapy with antiepileptic drugs. This study is concerned with identifying mechanistic links that connect seizure activity to increased P-glycoprotein expression at the blood-br...
Saved in:
Published in | Molecular pharmacology Vol. 73; no. 5; pp. 1444 - 1453 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Pharmacology and Experimental Therapeutics
01.05.2008
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Increased expression of drug efflux transporters at the blood-brain barrier accompanies epileptic seizures and complicates
therapy with antiepileptic drugs. This study is concerned with identifying mechanistic links that connect seizure activity
to increased P-glycoprotein expression at the blood-brain barrier. In this regard, we tested the hypothesis that seizures
increase brain extracellular glutamate, which signals through an N -methyl- d -aspartate (NMDA) receptor and cyclooxygenase-2 (COX-2) in brain capillaries to increase blood-brain barrier P-glycoprotein
expression. Consistent with this hypothesis, exposing isolated rat or mouse brain capillaries to glutamate for 15 to 30 min
increased P-glycoprotein expression and transport activity hours later. These increases were blocked by 5 H -dibenzo[ a , d ]cyclohepten-5,10-imine (dizocilpine maleate) (MK-801), an NMDA receptor antagonist, and by celecoxib, a selective COX-2 inhibitor;
no such glutamate-induced increases were seen in brain capillaries from COX-2-null mice. In rats, intracerebral microinjection
of glutamate caused locally increased P-glycoprotein expression in brain capillaries. Moreover, using a pilocarpine status
epilepticus rat model, we observed seizure-induced increases in capillary P-glycoprotein expression that were attenuated by
administration of indomethacin, a COX inhibitor. Our findings suggest that brain uptake of some antiepileptic drugs can be
enhanced through COX-2 inhibition. Moreover, they provide insight into one mechanism that underlies drug resistance in epilepsy
and possibly other central nervous system disorders. |
---|---|
AbstractList | Increased expression of drug efflux transporters at the blood-brain barrier accompanies epileptic seizures and complicates therapy with antiepileptic drugs. This study is concerned with identifying mechanistic links that connect seizure activity to increased P-glycoprotein expression at the blood-brain barrier. In this regard, we tested the hypothesis that seizures increase brain extracellular glutamate, which signals through an N-methyl-d-aspartate (NMDA) receptor and cyclooxygenase-2 (COX-2) in brain capillaries to increase blood-brain barrier P-glycoprotein expression. Consistent with this hypothesis, exposing isolated rat or mouse brain capillaries to glutamate for 15 to 30 min increased P-glycoprotein expression and transport activity hours later. These increases were blocked by 5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate) (MK-801), an NMDA receptor antagonist, and by celecoxib, a selective COX-2 inhibitor; no such glutamate-induced increases were seen in brain capillaries from COX-2-null mice. In rats, intracerebral microinjection of glutamate caused locally increased P-glycoprotein expression in brain capillaries. Moreover, using a pilocarpine status epilepticus rat model, we observed seizure-induced increases in capillary P-glycoprotein expression that were attenuated by administration of indomethacin, a COX inhibitor. Our findings suggest that brain uptake of some antiepileptic drugs can be enhanced through COX-2 inhibition. Moreover, they provide insight into one mechanism that underlies drug resistance in epilepsy and possibly other central nervous system disorders. Increased expression of drug efflux transporters at the blood-brain barrier accompanies epileptic seizures and complicates therapy with antiepileptic drugs. This study is concerned with identifying mechanistic links that connect seizure activity to increased P-glycoprotein expression at the blood-brain barrier. In this regard, we tested the hypothesis that seizures increase brain extracellular glutamate, which signals through an N -methyl- d -aspartate (NMDA) receptor and cyclooxygenase-2 (COX-2) in brain capillaries to increase blood-brain barrier P-glycoprotein expression. Consistent with this hypothesis, exposing isolated rat or mouse brain capillaries to glutamate for 15 to 30 min increased P-glycoprotein expression and transport activity hours later. These increases were blocked by 5 H -dibenzo[ a , d ]cyclohepten-5,10-imine (dizocilpine maleate) (MK-801), an NMDA receptor antagonist, and by celecoxib, a selective COX-2 inhibitor; no such glutamate-induced increases were seen in brain capillaries from COX-2-null mice. In rats, intracerebral microinjection of glutamate caused locally increased P-glycoprotein expression in brain capillaries. Moreover, using a pilocarpine status epilepticus rat model, we observed seizure-induced increases in capillary P-glycoprotein expression that were attenuated by administration of indomethacin, a COX inhibitor. Our findings suggest that brain uptake of some antiepileptic drugs can be enhanced through COX-2 inhibition. Moreover, they provide insight into one mechanism that underlies drug resistance in epilepsy and possibly other central nervous system disorders. |
Author | Heidrun Potschka Anton Pekcec David S. Miller Kathrin Toellner Björn Bauer Anika M. S. Hartz |
Author_xml | – sequence: 1 givenname: Björn surname: Bauer fullname: Bauer, Björn organization: Institute of Pharmacology, Toxicology, and Pharmacy, Ludwig-Maximilians-University Munich, Koeniginstr. 16, 80539 Munich, Germany – sequence: 2 givenname: Anika M S surname: Hartz fullname: Hartz, Anika M S – sequence: 3 givenname: Anton surname: Pekcec fullname: Pekcec, Anton – sequence: 4 givenname: Kathrin surname: Toellner fullname: Toellner, Kathrin – sequence: 5 givenname: David S surname: Miller fullname: Miller, David S – sequence: 6 givenname: Heidrun surname: Potschka fullname: Potschka, Heidrun |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18094072$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkEFv1DAQhS1URLeFK0fkEzcvtuMkzpFdwVKpEohSiZs160wSI8denEQQ-PMY7Uo9zWj03puZ74ZchRiQkNeCb4WQ6t0Y_VbwesuVkII_IxtRSsG4EOKKbDiXFdNN-f2a3EzTD86FKjV_Qa6F5o3itdyQvw_o_iwJ2V1oF4stfTyxr9gvHmYXA40d_cIOfrXxlOKMLlCY6Twg3fkYW7ZLkEc7SMlhyvMUl36gB7_MMMKMFEJL96vN2t9rjwEmZJI-uD6Ad6F_SZ534Cd8dam35PHjh2_7T-z-8-Fu__6eWSXFzJp8qrUCeAEN11WNtquOTS3LstUIWtRlo6EFa9URS6x0p7CwpdR1JbMVbHFL3p5z8w8_F5xmM7rJovcQMC6TkbxqMpEiC7dnoU1xmhJ25pTcCGk1gpv_uE3GnfvanHFnw5tL8nIcsX2SX_g-rR5cP_xyCc1pgDSCjT72q6kLUxqhlCr-AWZAi68 |
CitedBy_id | crossref_primary_10_1016_j_phrs_2015_02_001 crossref_primary_10_1016_j_biomaterials_2015_09_041 crossref_primary_10_3389_fnagi_2024_1368200 crossref_primary_10_1517_17425255_2016_1168804 crossref_primary_10_1371_journal_pone_0140918 crossref_primary_10_1016_j_biomaterials_2015_10_050 crossref_primary_10_3390_life13061294 crossref_primary_10_3389_fnins_2019_01358 crossref_primary_10_1111_ejn_15079 crossref_primary_10_1111_j_1528_1167_2010_02585_x crossref_primary_10_1007_s11095_022_03427_3 crossref_primary_10_1038_clpt_2009_138 crossref_primary_10_1038_scibx_2008_991 crossref_primary_10_1002_epi4_12590 crossref_primary_10_1155_2015_194541 crossref_primary_10_5059_yukigoseikyokaishi_73_254 crossref_primary_10_3389_fnins_2022_851394 crossref_primary_10_1016_j_nbd_2019_02_010 crossref_primary_10_1016_j_yebeh_2019_02_012 crossref_primary_10_1002_ana_23567 crossref_primary_10_1007_s11064_022_03803_w crossref_primary_10_1038_nrn2995 crossref_primary_10_1586_14737175_2016_1158101 crossref_primary_10_1111_epi_12461 crossref_primary_10_1016_j_brainres_2021_147303 crossref_primary_10_1016_j_bbcan_2023_188957 crossref_primary_10_1089_neu_2012_2587 crossref_primary_10_1016_j_neuropharm_2019_107742 crossref_primary_10_1016_j_addr_2011_11_008 crossref_primary_10_1016_j_ejphar_2022_175327 crossref_primary_10_1111_epi_17751 crossref_primary_10_1016_j_cotox_2018_12_004 crossref_primary_10_1038_s41467_023_36070_6 crossref_primary_10_1016_j_xcrm_2024_101609 crossref_primary_10_3390_cancers14174285 crossref_primary_10_1016_j_yebeh_2020_107659 crossref_primary_10_1016_j_eplepsyres_2008_10_010 crossref_primary_10_1016_j_hsr_2023_100141 crossref_primary_10_1016_j_eplepsyres_2014_02_012 crossref_primary_10_1124_mol_108_046680 crossref_primary_10_1208_s12248_017_0096_2 crossref_primary_10_2217_pgs_10_126 crossref_primary_10_1016_j_brainres_2011_04_003 crossref_primary_10_1016_j_phrs_2019_04_031 crossref_primary_10_1007_s11095_008_9735_8 crossref_primary_10_1111_j_1528_1167_2010_02671_x crossref_primary_10_1007_s12035_024_04274_6 crossref_primary_10_3109_00207454_2014_989321 crossref_primary_10_1111_j_1528_1167_2011_03034_x crossref_primary_10_1016_j_neuroscience_2014_10_021 crossref_primary_10_3389_fvets_2022_864293 crossref_primary_10_1177_0271678X15608644 crossref_primary_10_14581_jer_21003 crossref_primary_10_3390_molecules22030365 crossref_primary_10_1002_med_21573 crossref_primary_10_1124_pr_120_019539 crossref_primary_10_1038_jcbfm_2010_21 crossref_primary_10_1016_j_eplepsyres_2016_11_004 crossref_primary_10_1007_s00210_023_02485_7 crossref_primary_10_1016_j_yebeh_2024_109890 crossref_primary_10_1007_s11064_014_1499_4 crossref_primary_10_1073_pnas_1203534109 crossref_primary_10_1016_j_eplepsyres_2017_02_003 crossref_primary_10_1210_en_2012_1316 crossref_primary_10_1371_journal_pone_0125389 crossref_primary_10_1016_j_neuropharm_2014_05_002 crossref_primary_10_1186_s12974_019_1592_3 crossref_primary_10_1021_mp2001022 crossref_primary_10_3390_ijms232314667 crossref_primary_10_1111_j_1528_1167_2008_01916_x crossref_primary_10_1002_glia_22312 crossref_primary_10_1111_epi_14586 crossref_primary_10_1016_j_neurobiolaging_2009_08_014 crossref_primary_10_1021_mp4001102 crossref_primary_10_1016_j_neulet_2018_10_016 crossref_primary_10_1111_bcpt_12973 crossref_primary_10_1517_14740338_2015_1010508 crossref_primary_10_3233_JAD_201074 crossref_primary_10_36485_1561_6274_2021_25_1_83_89 crossref_primary_10_1002_sstr_202300508 crossref_primary_10_1096_fj_201901369RR crossref_primary_10_3390_cells13090740 crossref_primary_10_1111_epi_14505 crossref_primary_10_3390_membranes13060568 crossref_primary_10_1007_s10309_010_0105_2 crossref_primary_10_1248_bpb_34_360 crossref_primary_10_14814_phy2_15239 crossref_primary_10_1155_2013_648268 crossref_primary_10_2133_dmpk_DMPK_14_RG_004 crossref_primary_10_1111_epi_17063 crossref_primary_10_1016_j_brainres_2014_08_060 crossref_primary_10_1021_jm301084z crossref_primary_10_1080_14756366_2021_1956912 crossref_primary_10_1002_smll_202300395 crossref_primary_10_1007_s10695_020_00911_8 crossref_primary_10_1016_j_eplepsyres_2010_06_011 crossref_primary_10_1016_j_neuropharm_2009_09_012 crossref_primary_10_1124_jpet_114_218180 crossref_primary_10_2174_1389450120666190308144448 crossref_primary_10_1007_s12031_022_02056_0 crossref_primary_10_1002_cpt_64 crossref_primary_10_1016_j_nbd_2023_106249 crossref_primary_10_1080_14728222_2022_2039120 crossref_primary_10_1177_0271678X17705786 crossref_primary_10_3390_pharmaceutics12100966 crossref_primary_10_1016_j_yebeh_2019_07_031 crossref_primary_10_1007_s12035_024_03969_0 crossref_primary_10_1124_mol_116_107169 crossref_primary_10_1016_j_tvjl_2023_106014 crossref_primary_10_1016_j_expneurol_2019_04_002 crossref_primary_10_1016_j_drudis_2016_09_017 crossref_primary_10_1017_S1461145710001161 crossref_primary_10_1016_j_tvjl_2023_105956 crossref_primary_10_1016_j_neuropharm_2011_05_027 crossref_primary_10_1093_neuonc_nos199 crossref_primary_10_21508_1027_4065_2021_66_2_6_12 crossref_primary_10_1016_j_neurobiolaging_2015_05_020 crossref_primary_10_1021_mp500841w crossref_primary_10_1002_jps_24697 crossref_primary_10_2174_1871527319999200819093109 crossref_primary_10_1523_JNEUROSCI_2751_17_2018 crossref_primary_10_1016_j_pharmthera_2013_01_009 crossref_primary_10_1097_CCO_0b013e32833de99d crossref_primary_10_1016_j_neuroimage_2016_05_045 crossref_primary_10_1016_j_foodres_2017_10_010 crossref_primary_10_1016_j_heliyon_2020_e04557 crossref_primary_10_1016_j_yebeh_2019_106451 crossref_primary_10_1021_acs_molpharmaceut_6b00770 crossref_primary_10_1016_j_neuroimage_2011_11_029 crossref_primary_10_1515_revneuro_2017_0043 crossref_primary_10_1016_j_addr_2011_12_007 crossref_primary_10_1016_j_brainres_2019_146516 crossref_primary_10_1124_pharmrev_120_000025 crossref_primary_10_4155_fmc_09_137 crossref_primary_10_1248_yakushi_20_00127 crossref_primary_10_1016_j_seizure_2020_09_015 crossref_primary_10_1021_acschemneuro_8b00271 crossref_primary_10_1007_s11033_020_06033_x crossref_primary_10_1016_j_pharmthera_2009_10_004 crossref_primary_10_1038_s41598_020_59259_x crossref_primary_10_1016_j_neuropharm_2009_01_009 crossref_primary_10_1016_j_phrs_2008_10_002 crossref_primary_10_1016_j_plefa_2020_102056 crossref_primary_10_1248_bpb_b18_00937 crossref_primary_10_1016_j_nbd_2014_04_001 crossref_primary_10_1155_2011_670613 crossref_primary_10_1002_epi4_12537 crossref_primary_10_1517_17425255_4_10_1245 crossref_primary_10_1016_j_neuro_2022_04_010 crossref_primary_10_1016_j_brainres_2015_07_005 crossref_primary_10_1038_s41401_024_01257_0 crossref_primary_10_1111_j_1476_5381_2010_00765_x crossref_primary_10_1096_fj_201901460RR crossref_primary_10_1007_s40265_013_0059_6 crossref_primary_10_1016_j_pneurobio_2019_101680 crossref_primary_10_3390_ijms21020591 crossref_primary_10_1007_s12031_017_0897_x crossref_primary_10_1007_s00011_023_01700_8 crossref_primary_10_3390_pharmaceutics13122024 crossref_primary_10_4199_C00073ED1V01Y201303GBD002 crossref_primary_10_1111_vec_12605 crossref_primary_10_1111_j_1471_4159_2012_07890_x crossref_primary_10_1186_1471_2202_10_28 crossref_primary_10_1002_epi4_12376 crossref_primary_10_1016_j_ejps_2011_05_005 crossref_primary_10_1016_j_nbd_2010_04_006 crossref_primary_10_1186_s12987_020_00220_5 crossref_primary_10_1016_j_eplepsyres_2022_106939 crossref_primary_10_1179_1743132811Y_0000000055 crossref_primary_10_4236_jbm_2023_118014 crossref_primary_10_1016_j_neuroscience_2014_07_030 crossref_primary_10_1016_j_tvjl_2022_105828 crossref_primary_10_1124_pr_107_07109 crossref_primary_10_1159_000460513 crossref_primary_10_1124_jpet_109_152520 crossref_primary_10_1002_cpt_435 crossref_primary_10_1016_j_heliyon_2022_e09777 crossref_primary_10_1016_j_eplepsyres_2016_10_012 crossref_primary_10_1016_j_neuroscience_2010_06_073 crossref_primary_10_1016_j_eplepsyres_2018_07_008 crossref_primary_10_1016_j_arr_2024_102224 crossref_primary_10_3389_fneur_2017_00301 crossref_primary_10_3109_13880209_2011_571264 crossref_primary_10_3390_pharmaceutics14071376 crossref_primary_10_1016_j_pharmthera_2020_107554 crossref_primary_10_1111_j_1528_1167_2010_02886_x |
Cites_doi | 10.1016/0006-8993(88)90556-2 10.1016/0920-1211(94)00081-7 10.1016/j.brainres.2005.05.038 10.1016/j.neures.2006.06.003 10.1016/j.eplepsyres.2003.12.009 10.1038/jcbfm.1992.119 10.1369/jhc.4A6451.2005 10.1016/j.nbd.2004.07.023 10.1124/jpet.106.109876 10.1016/j.ejphar.2006.06.022 10.1016/j.lfs.2004.02.027 10.1074/jbc.M206855200 10.1016/S0197-0186(02)00101-8 10.1038/nrm1229 10.1002/ana.20078 10.1038/sj.jcbfm.9600445 10.1073/pnas.98.3.1294 10.1111/j.1528-1167.2006.00496.x 10.1016/S0006-8993(99)01797-7 10.1152/ajpheart.00520.2003 10.1124/mol.104.001503 10.1124/mol.106.023796 10.1016/j.nbd.2006.06.014 10.1358/mf.2003.25.2.723681 10.1124/mol.105.017954 10.1016/j.nbd.2007.04.002 10.1089/089771502753754091 10.1124/jpet.302.3.846 10.1016/S0920-1211(01)00272-8 10.1111/j.1471-4159.2005.03150.x 10.1124/mol.106.029512 10.1586/14737175.6.3.397 10.1016/j.nbd.2006.08.015 10.2174/0929867033456800 10.1016/S0306-4522(03)00027-7 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TK |
DOI | 10.1124/mol.107.041210 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Neurosciences Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Neurosciences Abstracts |
DatabaseTitleList | MEDLINE Neurosciences Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-0111 |
EndPage | 1453 |
ExternalDocumentID | 10_1124_mol_107_041210 18094072 73_5_1444 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Intramural |
GrantInformation_xml | – fundername: Intramural NIH HHS |
GroupedDBID | - 0R 123 2WC 34G 39C 4.4 53G 55 5RE 5VS AALRV AAPBV ABFLS ABSGY ABZEH ACGFS ADACO ADBIT ADCOW AENEX AFFNX ALMA_UNASSIGNED_HOLDINGS CS3 DIK DL E3Z EBS EJD F5P FH7 GX1 H13 HH5 HZ IH2 INIJC KQ8 L7B N9A O0- O9- OK1 P2P R.V R0Z RHF RHI RPT WOQ X X7M ZA5 --- -~X .55 .GJ 0R~ 18M AAJMC ABCQX ABJNI ABSQV ACGFO ADBBV AERNN AFHIN AFOSN AYCSE BAWUL BTFSW CGR CUY CVF ECM EIF F9R HZ~ K-O LSO MVM NPM TR2 UQL W8F XOL YBU YHG ZGI ZXP AAYXX CITATION 7TK |
ID | FETCH-LOGICAL-c421t-9940cc1a03a90867ecf6b97255d8ea817598adacc4be5e68f4e3c528762994ac3 |
ISSN | 0026-895X |
IngestDate | Fri Aug 16 21:44:08 EDT 2024 Fri Aug 23 00:48:33 EDT 2024 Sat Sep 28 07:52:37 EDT 2024 Tue Jan 05 21:17:31 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c421t-9940cc1a03a90867ecf6b97255d8ea817598adacc4be5e68f4e3c528762994ac3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 18094072 |
PQID | 20691803 |
PQPubID | 23462 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_20691803 crossref_primary_10_1124_mol_107_041210 pubmed_primary_18094072 highwire_pharmacology_73_5_1444 |
ProviderPackageCode | RHF RHI |
PublicationCentury | 2000 |
PublicationDate | 2008-05-01 |
PublicationDateYYYYMMDD | 2008-05-01 |
PublicationDate_xml | – month: 05 year: 2008 text: 2008-05-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular pharmacology |
PublicationTitleAlternate | Mol Pharmacol |
PublicationYear | 2008 |
Publisher | American Society for Pharmacology and Experimental Therapeutics |
Publisher_xml | – name: American Society for Pharmacology and Experimental Therapeutics |
References | 18314494 - Mol Pharmacol. 2008 May;73(5):1343-6 2019081413572856000_73.5.1444.2 2019081413572856000_73.5.1444.1 2019081413572856000_73.5.1444.6 2019081413572856000_73.5.1444.13 2019081413572856000_73.5.1444.35 2019081413572856000_73.5.1444.5 2019081413572856000_73.5.1444.12 2019081413572856000_73.5.1444.34 2019081413572856000_73.5.1444.15 2019081413572856000_73.5.1444.37 2019081413572856000_73.5.1444.3 2019081413572856000_73.5.1444.14 2019081413572856000_73.5.1444.36 2019081413572856000_73.5.1444.31 2019081413572856000_73.5.1444.9 2019081413572856000_73.5.1444.8 2019081413572856000_73.5.1444.11 2019081413572856000_73.5.1444.33 2019081413572856000_73.5.1444.7 2019081413572856000_73.5.1444.10 2019081413572856000_73.5.1444.32 (2019081413572856000_73.5.1444.24) 2001; 297 2019081413572856000_73.5.1444.17 2019081413572856000_73.5.1444.39 2019081413572856000_73.5.1444.38 2019081413572856000_73.5.1444.19 2019081413572856000_73.5.1444.18 2019081413572856000_73.5.1444.40 (2019081413572856000_73.5.1444.16) 2002; 59 (2019081413572856000_73.5.1444.30) 1995; 268 2019081413572856000_73.5.1444.23 2019081413572856000_73.5.1444.26 2019081413572856000_73.5.1444.25 2019081413572856000_73.5.1444.20 2019081413572856000_73.5.1444.22 2019081413572856000_73.5.1444.21 2019081413572856000_73.5.1444.28 2019081413572856000_73.5.1444.27 2019081413572856000_73.5.1444.29 (2019081413572856000_73.5.1444.4) 2004; 66 |
References_xml | – ident: 2019081413572856000_73.5.1444.18 doi: 10.1016/0006-8993(88)90556-2 – ident: 2019081413572856000_73.5.1444.26 – volume: 66 start-page: 413 year: 2004 ident: 2019081413572856000_73.5.1444.4 publication-title: Mol Pharmacol – ident: 2019081413572856000_73.5.1444.35 doi: 10.1016/0920-1211(94)00081-7 – ident: 2019081413572856000_73.5.1444.19 doi: 10.1016/j.brainres.2005.05.038 – ident: 2019081413572856000_73.5.1444.34 doi: 10.1016/j.neures.2006.06.003 – ident: 2019081413572856000_73.5.1444.38 doi: 10.1016/j.eplepsyres.2003.12.009 – ident: 2019081413572856000_73.5.1444.29 doi: 10.1038/jcbfm.1992.119 – ident: 2019081413572856000_73.5.1444.37 doi: 10.1369/jhc.4A6451.2005 – ident: 2019081413572856000_73.5.1444.39 doi: 10.1016/j.nbd.2004.07.023 – ident: 2019081413572856000_73.5.1444.15 doi: 10.1124/jpet.106.109876 – ident: 2019081413572856000_73.5.1444.11 doi: 10.1016/j.ejphar.2006.06.022 – volume: 297 start-page: 1051 year: 2001 ident: 2019081413572856000_73.5.1444.24 publication-title: J Pharmacol Exp Ther – ident: 2019081413572856000_73.5.1444.40 doi: 10.1016/j.lfs.2004.02.027 – ident: 2019081413572856000_73.5.1444.25 doi: 10.1074/jbc.M206855200 – ident: 2019081413572856000_73.5.1444.10 doi: 10.1016/S0197-0186(02)00101-8 – ident: 2019081413572856000_73.5.1444.22 doi: 10.1038/nrm1229 – ident: 2019081413572856000_73.5.1444.23 doi: 10.1002/ana.20078 – ident: 2019081413572856000_73.5.1444.1 doi: 10.1038/sj.jcbfm.9600445 – ident: 2019081413572856000_73.5.1444.17 doi: 10.1073/pnas.98.3.1294 – ident: 2019081413572856000_73.5.1444.36 doi: 10.1111/j.1528-1167.2006.00496.x – ident: 2019081413572856000_73.5.1444.2 doi: 10.1016/S0006-8993(99)01797-7 – ident: 2019081413572856000_73.5.1444.32 doi: 10.1152/ajpheart.00520.2003 – ident: 2019081413572856000_73.5.1444.13 doi: 10.1124/mol.104.001503 – ident: 2019081413572856000_73.5.1444.6 doi: 10.1124/mol.106.023796 – ident: 2019081413572856000_73.5.1444.7 doi: 10.1016/j.nbd.2006.06.014 – ident: 2019081413572856000_73.5.1444.31 doi: 10.1358/mf.2003.25.2.723681 – ident: 2019081413572856000_73.5.1444.14 doi: 10.1124/mol.105.017954 – ident: 2019081413572856000_73.5.1444.27 doi: 10.1016/j.nbd.2007.04.002 – volume: 268 start-page: F46 year: 1995 ident: 2019081413572856000_73.5.1444.30 publication-title: Am J Physiol – volume: 59 start-page: S3 issue: Suppl 5 year: 2002 ident: 2019081413572856000_73.5.1444.16 publication-title: Neurology – ident: 2019081413572856000_73.5.1444.33 doi: 10.1089/089771502753754091 – ident: 2019081413572856000_73.5.1444.9 doi: 10.1124/jpet.302.3.846 – ident: 2019081413572856000_73.5.1444.12 doi: 10.1016/S0920-1211(01)00272-8 – ident: 2019081413572856000_73.5.1444.28 doi: 10.1111/j.1471-4159.2005.03150.x – ident: 2019081413572856000_73.5.1444.5 doi: 10.1124/mol.106.029512 – ident: 2019081413572856000_73.5.1444.20 doi: 10.1586/14737175.6.3.397 – ident: 2019081413572856000_73.5.1444.21 doi: 10.1016/j.nbd.2006.08.015 – ident: 2019081413572856000_73.5.1444.3 doi: 10.2174/0929867033456800 – ident: 2019081413572856000_73.5.1444.8 doi: 10.1016/S0306-4522(03)00027-7 |
SSID | ssj0014580 |
Score | 2.435986 |
Snippet | Increased expression of drug efflux transporters at the blood-brain barrier accompanies epileptic seizures and complicates
therapy with antiepileptic drugs.... Increased expression of drug efflux transporters at the blood-brain barrier accompanies epileptic seizures and complicates therapy with antiepileptic drugs.... |
SourceID | proquest crossref pubmed highwire |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1444 |
SubjectTerms | Animals ATP-Binding Cassette, Sub-Family B, Member 1 - genetics Blood-Brain Barrier - drug effects Blood-Brain Barrier - enzymology Blood-Brain Barrier - pathology Capillaries - drug effects Capillaries - enzymology Capillaries - pathology Cyclooxygenase 2 - metabolism Female Glutamic Acid - pharmacology Hippocampus - drug effects Hippocampus - enzymology Indomethacin Male Mice Mice, Inbred C57BL Pilocarpine Protein Biosynthesis - drug effects Rats Rats, Sprague-Dawley Rats, Wistar Receptors, N-Methyl-D-Aspartate - metabolism Seizures - chemically induced Seizures - pathology Signal Transduction - drug effects Transcription, Genetic - drug effects Up-Regulation - genetics |
Title | Seizure-Induced Up-Regulation of P-Glycoprotein at the Blood-Brain Barrier through Glutamate and Cyclooxygenase-2 Signaling |
URI | http://molpharm.aspetjournals.org/content/73/5/1444.abstract https://www.ncbi.nlm.nih.gov/pubmed/18094072 https://search.proquest.com/docview/20691803 |
Volume | 73 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKeOEFcadsgB_QeOg8msRJ7Md12kVojIqlUt8sx3GmspJUXSvR8Qf42RzHTpMOEJeXKIpyU74v52L7fAehN0EacG2GwDJNFaHKzwhLwz6heW6EUFmUVeXRH86j0xF9Pw7Hnc731qql5SLdVze_rCv5H1ThGOBqqmT_Adn1TeEA7AO-sAWEYftXGF_oyc1yronpv2Hm8Ucz8sn2lndh4JCcTFeqrMQYJoUrXOwNqsXqA9Mcwsw3VD3r6n49J_C-EqJYO6twuFJw7tcVvAF4O-L3LiaXJnJ37q7uBFW32O3NGiHsplBCLi0tBp9LPS8akzevWsn2DorJlWyNjQ_1ldLKCRs0iwSSUk-nRbMEZO4kw-sRC9asD1xXEESE8XBsfZAzvL4Z1nCG11lm2-TEMTBsmVnIAmnLZXvUCg7_7A58Chh-Kaf7npGqpEYtrXF89WT_-UdxPDo7E8nROLmD7vpgsqLKxK8TKXgAs8VM7s2d_Cfc_93m3TfDm1py-vfpSxXGJA_QfZd_4ANLpoeoo4tHaHdocVvt4aSpx7vew7t42EL0Mfp2i3F4g3G4zPEm47BcYGAcbjEOO8Zhxzi8ZhwGxuHbjMNrxj1Bo-Oj5PCUuPYdRFHfWxDOaV8pT_YDySFxjrXKo5THkMNmTEsGcStnMpNK0VSHOmI51YEKfeOe4VKpgqdoqygL_RzhKI1CbjIDL_OoZAqyfJbFXkp5zkJf8S56W391MbMqLaLKbn0qAB_Yj4XFp4te16CI9j8h4kCEwvAKzqixEmBqzfyZLHS5vBZ-P-Ie6wdd9MxC2DyLGRnK2H_xx2u30b3ml9hBW4v5Ur-EsHaRvqoY9wPj_qZn |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | ABC ChemistRy |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Seizure-Induced+Up-Regulation+of+P-Glycoprotein+at+the+Blood-Brain+Barrier+through+Glutamate+and+Cyclooxygenase-2+Signaling&rft.jtitle=Molecular+pharmacology&rft.au=Bauer%2C+Bjoern&rft.au=Hartz%2C+Anika+MS&rft.au=Pekcec%2C+Anton&rft.au=Toellner%2C+Kathrin&rft.date=2008-05-01&rft.issn=0026-895X&rft.eissn=1521-0111&rft.volume=73&rft.issue=5&rft.spage=1444&rft.epage=1453&rft_id=info:doi/10.1124%2Fmol.107.041210&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0026-895X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0026-895X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0026-895X&client=summon |